Eli Lilly and Company announced on Monday that it has entered into a definitive agreement to acquire Orna Therapeutics, a Watertown, Massachusetts-based biotechnology company developing a novel class of circular RNA therapeutics, for up to $2.4 billion in cash. The deal includes an upfront payment and additional milestone-based payments contingent on clinical development progress. It represents Lilly's most significant move yet into the rapidly emerging field of in vivo cell therapy, a technology that could fundamentally alter how patients with autoimmune diseases are treated.
The acquisition is Lilly's second deal announcement in as many days, following a separate licensing agreement, and underscores the pharmaceutical giant's determination to build a pipeline that extends well beyond the GLP-1 weight-loss franchise that has powered its rise to a market capitalization exceeding $800 billion. With Orna, Lilly is placing a bet that the next revolution in medicine will come not from injectable drugs but from reprogramming the body's own immune system, directly inside the patient, using engineered RNA molecules.
What Makes Orna's Technology Different
Traditional CAR-T (Chimeric Antigen Receptor T-cell) therapy, which has shown remarkable efficacy in treating certain blood cancers, requires an extraordinarily complex and expensive process. A patient's T-cells are extracted through a procedure called leukapheresis, shipped to a specialized manufacturing facility, genetically modified to target specific proteins on diseased cells, expanded in culture, and then infused back into the patient. The entire process can take weeks, costs hundreds of thousands of dollars per treatment, and requires specialized hospital infrastructure that limits access to major academic medical centers.
Orna's approach eliminates virtually all of that complexity. The company has developed a proprietary circular RNA (oRNA) platform that can be injected directly into a patient's bloodstream, where it enters T-cells and instructs them to produce chimeric antigen receptors on their surfaces. In essence, the therapy turns the patient's own body into the manufacturing facility, programming immune cells to attack disease targets without ever removing them from the body.
"Orna's in vivo approach to CAR-T therapy has the potential to dramatically expand patient access by eliminating the need for complex cell manufacturing. If successful, this could transform autoimmune disease treatment from a hospital-based procedure into something much closer to a standard infusion."
Daniel Skovronsky, Chief Scientific Officer, Eli Lilly
The Autoimmune Disease Opportunity
Orna's lead program, ORN-252, is a clinical trial-ready therapy that targets CD19, a protein found on the surface of B cells. B cells are central players in many autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, and myasthenia gravis. By programming T-cells to eliminate pathogenic B cells, the therapy aims to reset the immune system and achieve durable remission without the chronic immunosuppression required by current treatments.
Early clinical data from ex vivo CAR-T therapies targeting CD19 in autoimmune diseases have generated significant excitement in the medical community. Small trials in patients with severe lupus and other conditions have shown complete remission rates that far exceed those of any existing therapy. The challenge has been scaling these treatments beyond the handful of specialized centers equipped to perform the complex manufacturing process. Orna's in vivo approach, if it works as intended, could make this transformative therapy available to the millions of Americans living with autoimmune conditions.
Circular RNA: A Platform With Broad Potential
Beyond CAR-T therapy, Orna's circular RNA platform has structural advantages over traditional messenger RNA (mRNA) technology. Circular RNA molecules lack the free ends that cellular enzymes use to degrade linear mRNA, giving them inherently longer stability and potentially longer-lasting protein expression. They also have simplified manufacturing processes compared to mRNA therapeutics, which require complex capping and tail modifications.
Lilly sees the platform as a foundation for multiple therapeutic applications beyond autoimmune disease. The company's press release noted that circular RNA could be used to deliver a wide range of therapeutic proteins directly to cells throughout the body, opening potential applications in oncology, rare diseases, and regenerative medicine.
The Competitive Landscape Is Heating Up
Lilly is far from alone in recognizing the potential of in vivo cell therapy. Several other pharmaceutical giants and biotechnology companies are pursuing similar approaches, though through different technological pathways. The race to develop an effective, scalable in vivo CAR-T platform has become one of the most closely watched competitions in drug development.
The $2.4 billion price tag, while substantial, is modest relative to the potential market. The global autoimmune disease therapeutics market exceeds $100 billion annually and continues to grow as diagnostic rates increase and new indications are identified. If Orna's technology proves successful in clinical trials, it could capture a meaningful share of that market while simultaneously expanding it by reaching patients who currently lack access to advanced cell therapies.
What the Deal Means for Lilly's Portfolio
For Eli Lilly, the Orna acquisition addresses a strategic vulnerability that investors have increasingly flagged: over-reliance on the GLP-1 franchise. While Zepbound and Mounjaro have generated extraordinary revenue growth, driving Lilly's stock to record highs, the weight-loss drug market is becoming increasingly competitive. Novo Nordisk's recent warning about potential 2026 sales declines and the emergence of lower-cost alternatives have reminded investors that no pharmaceutical franchise is permanent.
By building a pipeline in cell therapy, Lilly is positioning itself for a future where the next generation of blockbuster drugs may not be small molecules or injectable biologics at all, but rather programmable therapeutics that harness the body's own cellular machinery. The Orna deal, combined with Lilly's existing investments in genetic medicine and protein engineering, gives the company one of the most diversified pipelines in the pharmaceutical industry.
The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory approvals. Orna's approximately 200 employees are expected to join Lilly's research organization.
